Combination therapies for the stimulation of bone growth
AssigneePfizer Inc.
InventorVishwas M. Paralkar
Life of this patent
Estimating the term…
Abstract
This invention relates to pharmaceutical combinations of a prostaglandin agonist and a HMG-CoA reductase inhibitor, methods of using such combinations and kits containing such combinations. The pharmaceutical combinations, methods and kits are useful to enhance bone formation in mammals, including humans.
Claims29
A pharmaceutical composition comprising a therapeutically effective amount of a first compound, said first compound being a prostaglandin agonist, or a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug, and a therapeutically effective amount of a second compound, said second compound being a HMG-CoA reductase inhibitor, or a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug.
2 A pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable vehicle, carrier or diluent.
A method of treating cartilage defects or disorders or promoting wound healing comprising administering to a mammal:
- a therapeutically effective amount of a first compound, said first compound being a prostaglandin agonist, prodrugs thereof and pharmaceutically acceptable salts of said prostaglanidin agonist and said prodrugs;
- and
- a therapeutically effective amount of a second compound, said second compound being a HMG-CoA reductase inhibitor, prodrugs thereof and pharmaceutically acceptable salts of said inhibitor and said prodrugs.
A kit comprising:
- a. an amount of a first compound, said first compound being a prostaglandin agonist, prodrugs thereof and pharmaceutically acceptable salts of said compound and said prodrugs in a first dosage form;
- b. an amount of a second compound, said second compound being a HMG-CoA reductase inhibitor, prodrugs thereof and pharmaceutically acceptable salts of said compound and said prodrugs in a second dosage form;
- and
- c. a container.
A method of treating cartilage defects or disorders or promoting wound healing comprising administering to a mammal:
- a therapeutically effective amount of a first compound, said first compound being (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid, a prodrug thereof or a pharmaceutically acceptable salt of said first compound or said prodrug;
- and
- a therapeutically effective amount of a second compound, said second compound being atorvastatin, a prodrug thereof or a pharmaceutically acceptable salt of said second compound or said prodrug.
Dependencies are inferred from the claim text.